# Zai Lab Ltd (ZLAB)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/zai-lab-ltd/ JSON: https://steadybase.io/company/zai-lab-ltd.json Checked Nov 21, 2026. Latest filing read: Nov 5, 2026.

## Company

- Legal name: Zai Lab Ltd
- Ticker: ZLAB (Nasdaq)
- SEC CIK: 0001704292
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Shanghai
- Fiscal year ends: December 31
- SEC filer category: Large accelerated filer
- Website: zailaboratory.com
- LinkedIn: https://www.linkedin.com/company/zai-lab
- Next earnings date: Feb 4, 2027 (estimated from past 8-K timing)

## Key facts

- Revenue: $460.2M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1704292/000170429226000015/0001704292-26-000015-index.html
- Operating income: -$229.4M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1704292/000170429226000015/0001704292-26-000015-index.html
- Net income: -$175.5M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1704292/000170429226000015/0001704292-26-000015-index.html
- SG&A: $277.6M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1704292/000170429226000015/0001704292-26-000015-index.html
- Employees: 1,784 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1704292/000170429226000015/zlab-20251231.htm
- Shares outstanding: 88,592,343 as of Feb 26, 2021 (10-K filed Mar 1, 2021). Source: https://www.sec.gov/Archives/edgar/data/1704292/000119312521062279/0001193125-21-062279-index.html
- Auditor: Kpmg LLP, Short Hills, New Jersey, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1704292/000170429226000015/zlab-20251231.htm

## Business

We are a patient-focused, innovative, commercial-stage, global biopharmaceutical company with a substantial presence in both Greater China and the United States. We are focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. We intend to leverage our competencies and resources to positively impact human health.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1704292/000170429226000015/zlab-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $460.2M | -$229.4M | -$175.5M | $277.6M |
| Dec 31, 2024 | $399.0M | -$282.1M | -$257.1M | $298.7M |
| Dec 31, 2023 | $266.7M | -$366.6M | -$334.6M | $281.6M |
| Dec 31, 2022 | $215.0M | -$404.4M | -$443.3M | $259.0M |
| Dec 31, 2021 | $144.3M | -$700.1M | -$704.5M | $218.8M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/zai-lab-ltd.json

## Officers and directors

- Ying Du, Chairperson & CEO. Source: Form 4 filed Jul 6, 2026, https://www.sec.gov/Archives/edgar/data/1704292/000090514826003167/0000905148-26-003167-index.htm
- Yajing Chen, Chief Financial Officer. Source: Form 4 filed Aug 21, 2026, https://www.sec.gov/Archives/edgar/data/1704292/000090514826003867/0000905148-26-003867-index.htm
- Rafael Amado, President and Head of Global Research and Development. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1704292/000170429226000015/zlab-20251231.htm
- Frazor Titus Edmondson III, Chief Legal Officer. Source: Form 4 filed Jun 29, 2026, https://www.sec.gov/Archives/edgar/data/1704292/000090514826003123/0000905148-26-003123-index.htm
- Yizhe Wang, Operating Partner. Source: Form 4 filed Jun 8, 2026, https://www.sec.gov/Archives/edgar/data/1704292/000090514826002826/0000905148-26-002826-index.htm
- Richard Gaynor, director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1704292/000170429226000015/zlab-20251231.htm
- F. Ty Edmondson, Named in proxy. Source: DEF 14A filed Apr 28, 2026, https://www.sec.gov/Archives/edgar/data/1704292/000170429226000030/zlab-20260428.htm
- John David Diekman, Board member (per proxy). Source: DEF 14A filed Apr 28, 2026, https://www.sec.gov/Archives/edgar/data/1704292/000170429226000030/zlab-20260428.htm
- Nisa Bernice Wing-Yu Leung, Board member (per proxy). Source: DEF 14A filed Apr 28, 2026, https://www.sec.gov/Archives/edgar/data/1704292/000170429226000030/zlab-20260428.htm
- Rafael G. Amado, Named in proxy. Source: DEF 14A filed Apr 28, 2026, https://www.sec.gov/Archives/edgar/data/1704292/000170429226000030/zlab-20260428.htm
- Richard Brian Gaynor, Board member (per proxy). Source: DEF 14A filed Apr 28, 2026, https://www.sec.gov/Archives/edgar/data/1704292/000170429226000030/zlab-20260428.htm
- Samantha (Ying) Du, Board member (per proxy). Source: DEF 14A filed Apr 28, 2026, https://www.sec.gov/Archives/edgar/data/1704292/000170429226000030/zlab-20260428.htm

## Recent 8-K events

- Nov 5, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1704292/000162828026070517/zlab-20261105.htm
- Oct 23, 2026: Item 1.01, Entry into a material definitive agreement; Item 3.02, Unregistered sales of equity securities; Item 7.01, Regulation FD disclosure; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1704292/000162828026066969/zlab-20261022.htm
- Aug 6, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1704292/000162828026053791/zlab-20260806.htm
- Jun 17, 2026: Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/1704292/000162828026043869/zlab-20260617.htm
- May 21, 2026: Item 5.02, Departure or appointment of directors or officers; compensation. Source: https://www.sec.gov/Archives/edgar/data/1704292/000162828026037387/zlab-20260518.htm
- May 7, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1704292/000162828026031624/zlab-20260507.htm
- Feb 26, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1704292/000170429226000014/zlab-20260226.htm
- Nov 6, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1704292/000170429225000023/zlab-20251106.htm
- Oct 16, 2025: Item 1.01, Entry into a material definitive agreement; Item 2.03, Creation of a direct financial obligation; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1704292/000170429225000014/zlab-20251013.htm
- Aug 7, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1704292/000162828025038547/zlab-20250807.htm

## Insider trades (Form 4)

- Nov 10, 2026: Richard Gaynor (Director) bought 1,228 shares, about $33,389. Source: https://www.sec.gov/Archives/edgar/data/1704292/000090514826004801/0000905148-26-004801-index.htm
- Aug 19, 2026: Yajing Chen (Chief Financial Officer) sold 260 shares, about $7,020. Source: https://www.sec.gov/Archives/edgar/data/1704292/000090514826003867/0000905148-26-003867-index.htm
- Aug 12, 2026: William Lis (Director) sold 8,506 shares, about $212,650. Source: https://www.sec.gov/Archives/edgar/data/1704292/000090514826003620/0000905148-26-003620-index.htm
- Aug 11, 2026: Yajing Chen (Chief Financial Officer) sold 619 shares, about $15,475. Source: https://www.sec.gov/Archives/edgar/data/1704292/000090514826003619/0000905148-26-003619-index.htm
- Jul 1, 2026: Richard Gaynor (Director) bought 1,736 shares, about $33,071. Source: https://www.sec.gov/Archives/edgar/data/1704292/000090514826003169/0000905148-26-003169-index.htm
- Jun 30, 2026: Ying Du (Chairperson & CEO) sold 7,026 shares, about $130,192. Source: https://www.sec.gov/Archives/edgar/data/1704292/000090514826003140/0000905148-26-003140-index.htm
- Jun 26, 2026: Frazor Titus Edmondson III (Chief Legal Officer) sold 4,103 shares, about $71,638. Source: https://www.sec.gov/Archives/edgar/data/1704292/000090514826003123/0000905148-26-003123-index.htm
- Jun 26, 2026: Ying Du (Chairperson & CEO) sold 24,543 shares, about $428,521. Source: https://www.sec.gov/Archives/edgar/data/1704292/000090514826003122/0000905148-26-003122-index.htm
- Jun 26, 2026: Yajing Chen (Chief Financial Officer) sold 2,264 shares, about $39,529. Source: https://www.sec.gov/Archives/edgar/data/1704292/000090514826003121/0000905148-26-003121-index.htm
- Jun 22, 2026: William Lis (Director) sold 7,040 shares, about $127,354. Source: https://www.sec.gov/Archives/edgar/data/1704292/000090514826003077/0000905148-26-003077-index.htm
- May 18, 2026: Ying Du (Chairperson & CEO) sold 100,000 shares, about $2.0M. Source: https://www.sec.gov/Archives/edgar/data/1704292/000090514826002524/0000905148-26-002524-index.htm
- May 14, 2026: Frazor Titus Edmondson III (Chief Legal Officer) sold 3,517 shares, about $71,008. Source: https://www.sec.gov/Archives/edgar/data/1704292/000090514826002404/0000905148-26-002404-index.htm
- May 14, 2026: Ying Du (Chairperson & CEO) sold 100,000 shares, about $2.0M. Source: https://www.sec.gov/Archives/edgar/data/1704292/000090514826002403/0000905148-26-002403-index.htm
- Apr 6, 2026: Joshua L. Smiley (See Remarks) sold 3,017 shares, about $61,698. Source: https://www.sec.gov/Archives/edgar/data/1704292/000090514826001607/0000905148-26-001607-index.htm
- Apr 6, 2026: Frazor Titus Edmondson III (Chief Legal Officer) sold 1,224 shares, about $25,031. Source: https://www.sec.gov/Archives/edgar/data/1704292/000090514826001606/0000905148-26-001606-index.htm

## What management said

- "We are approaching a defining period for Zai Lab, as we advance toward bringing our first internally developed innovative medicines to patients globally" Dr. Samantha Du, Founder, Chairperson and Chief Executive Officer of Zai Lab (8-K filed Nov 5, 2026). Source: https://www.sec.gov/Archives/edgar/data/1704292/000162828026070517/zlab-2026115x8kex991.htm

## Latest filings

- 8-K filed Oct 23, 2026: https://www.sec.gov/Archives/edgar/data/1704292/000162828026066969/zlab-20261022.htm
- 10-K filed Feb 26, 2026: https://www.sec.gov/Archives/edgar/data/1704292/000170429226000015/zlab-20251231.htm
- 10-Q filed Aug 6, 2026: https://www.sec.gov/Archives/edgar/data/1704292/000162828026053793/zlab-20260630.htm
- 20f filed Apr 29, 2020: https://www.sec.gov/Archives/edgar/data/1704292/000156459020019745/zlab-20f_20191231.htm
- DEF 14A filed Apr 28, 2026: https://www.sec.gov/Archives/edgar/data/1704292/000170429226000030/zlab-20260428.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/

